For example, the synthetic CB1 antagonist rimonabant, marketed as an appetite suppressor, was withdrawn because 26% of patients reported depression, anxiety, and feeling of suicidality (Lazary, Juhasz, Hunyady, & Bagdy, 2011). Here, CNR1 is linked to major depressive disorder.